Aligos Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 29.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Details
| Name | Aligos Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 82 |
| Founded | 2018 |
| Ipo Date | 2020-10-16 |
| Ceo | Lawrence Blatt |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 15.00 |
| Isin | US01626L2043 |
| Cusip | 01626L204 |
| Cik | 0001799448 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Lawrence M. Blatt MBA, Ph.D. | Chief Executive Officer, President and Chairman of the Board |
| Lesley Ann Calhoun CPA | Executive Vice President, Chief Financial Officer and Chief Operating Officer |
| Dr. Julian A. Symons DPHIL | Executive Vice President and Chief Scientific Officer |
| Nikhil Aneja | Principal Accounting Officer |
| Laura Kavanaugh | Vice President and Head of Legal |
| Kristina Engeseth M.B.A. | Senior Vice President and Head of People and Culture |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President and Chief Development Officer |
| Dr. David B. Smith Ph.D. | Executive Vice President and Head of Chemical Operations |
| Dr. Tse-I Lin Ph.D. | Senior Vice President of Early Compound Development and Belgian Site Head |
| Dr. Kieron Wesson Ph.D. | Vice President and Head of Chemistry Manufacturing Controls |
Contact
| Address | One Corporate Drive, 2nd Floor, South San Francisco, California 94080, United States |
| Phone | 800 466 6059 |
| Website | https://www.aligos.com |